Ravi Thadhani1,2, Ruffy Guilatco3, Jeffrey Hymes4, Franklin W Maddux4, Ajay Ahuja5. 1. Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA. 2. Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA. 3. Pfizer Essential Health, Clinical Development and Medical Affairs, Pfizer Inc., Makati City, Philippines. 4. Fresenius Medical Care North America, Waltham, Massachusetts, USA. 5. Pfizer Essential Health, Clinical Development and Medical Affairs, Pfizer Inc., Lake Forest, Illinois, USA.
Abstract
BACKGROUND: For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESAs) are typically dosed via precise algorithms. Using one such algorithm, we assessed the maintenance of hemoglobin levels in patients switched from epoetin alfa reference product (Epogen®) to epoetin alfa-epbx (RetacritTM; a biosimilar to US-licensed Epogen®/Procrit®). METHODS: This randomized, open-label, non-inferiority study was conducted at Fresenius Medical Care North America (FMCNA) hemodialysis centers. Patients with anemia and chronic kidney disease undergoing maintenance hemodialysis and receiving routine intravenous (IV) Epogen® were randomized 1: 1 to switch to IV RetacritTM or continue standard-of-care (Epogen®) for 24 weeks, using analogous versions of the FMCNA ESA-dosing algorithm. The primary endpoint was the proportion of time patients' hemoglobin was 9-11 g/dL during weeks 17-24. RESULTS:Of 432 randomized patients, 418 received treatment (RetacritTM, n = 212; standard-of-care, n = 206) and comprised the full analysis set. A similar proportion of patients discontinued from each arm. The proportion of time patients' hemoglobin was within the target range was 61.9% (95% CI 57.5-66.2) in the RetacritTM arm and 63.3% (95% CI 58.7-67.7) in the standard-of-care arm. The difference in proportions between treatment arms was -1.4% (95% CI -7.6 to 4.9), and the lower bound of the confidence interval was within the pre-specified non-inferiority margin of -12.5%. There was no statistically significant difference between arms in the mean change from baseline in the weekly mean ESA dose during weeks 17-24, and no clinically relevant differences in safety outcomes. CONCLUSIONS: Switching to RetacritTM was non-inferior to continuing -Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials.gov, NCT02504294).
RCT Entities:
BACKGROUND: For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESAs) are typically dosed via precise algorithms. Using one such algorithm, we assessed the maintenance of hemoglobin levels in patients switched from epoetin alfa reference product (Epogen®) to epoetin alfa-epbx (RetacritTM; a biosimilar to US-licensed Epogen®/Procrit®). METHODS: This randomized, open-label, non-inferiority study was conducted at Fresenius Medical Care North America (FMCNA) hemodialysis centers. Patients with anemia and chronic kidney disease undergoing maintenance hemodialysis and receiving routine intravenous (IV) Epogen® were randomized 1: 1 to switch to IV RetacritTM or continue standard-of-care (Epogen®) for 24 weeks, using analogous versions of the FMCNA ESA-dosing algorithm. The primary endpoint was the proportion of time patients' hemoglobin was 9-11 g/dL during weeks 17-24. RESULTS: Of 432 randomized patients, 418 received treatment (RetacritTM, n = 212; standard-of-care, n = 206) and comprised the full analysis set. A similar proportion of patients discontinued from each arm. The proportion of time patients' hemoglobin was within the target range was 61.9% (95% CI 57.5-66.2) in the RetacritTM arm and 63.3% (95% CI 58.7-67.7) in the standard-of-care arm. The difference in proportions between treatment arms was -1.4% (95% CI -7.6 to 4.9), and the lower bound of the confidence interval was within the pre-specified non-inferiority margin of -12.5%. There was no statistically significant difference between arms in the mean change from baseline in the weekly mean ESA dose during weeks 17-24, and no clinically relevant differences in safety outcomes. CONCLUSIONS: Switching to RetacritTM was non-inferior to continuing -Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials.gov, NCT02504294).
Authors: Steven Fishbane; Bhupinder Singh; Seema Kumbhat; Wayne A Wisemandle; Nancy E Martin Journal: Clin J Am Soc Nephrol Date: 2018-06-19 Impact factor: 8.237
Authors: Nathan W Levin; Steven Fishbane; Francisco Valdés Cañedo; Steven Zeig; George M Nassar; John E Moran; Giuseppe Villa; Ulrich Beyer; Delphine Oguey Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Steven Fishbane; Brigitte Schiller; Francesco Locatelli; Adrian C Covic; Robert Provenzano; Andrzej Wiecek; Nathan W Levin; Mark Kaplan; Iain C Macdougall; Carol Francisco; Martha R Mayo; Krishna R Polu; Anne-Marie Duliege; Anatole Besarab Journal: N Engl J Med Date: 2013-01-24 Impact factor: 91.245
Authors: David Goldsmith; Frank Dellanna; Martin Schiestl; Andriy Krendyukov; Christian Combe Journal: Clin Drug Investig Date: 2018-06 Impact factor: 2.859
Authors: Carlo Barbieri; Elena Bolzoni; Flavio Mari; Isabella Cattinelli; Francesco Bellocchio; José D Martin; Claudia Amato; Andrea Stopper; Emanuele Gatti; Iain C Macdougall; Stefano Stuard; Bernard Canaud Journal: PLoS One Date: 2016-03-03 Impact factor: 3.240
Authors: Pier Luigi Zinzani; Martin Dreyling; William Gradishar; Marc Andre; Francisco J Esteva; Suliman Boulos; Eva González Barca; Giuseppe Curigliano Journal: Drugs Date: 2019-10 Impact factor: 9.546